Literature DB >> 22503057

First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes.

Anouar Belkacemi1, Pierfrancesco Agostoni, Hendrik M Nathoe, Michiel Voskuil, ChunLai Shao, Eric Van Belle, Thierry Wildbergh, Luigi Politi, Pieter A Doevendans, Giuseppe M Sangiorgi, Pieter R Stella.   

Abstract

OBJECTIVES: The goal of this study was to compare angiographic, intravascular imaging, and functional parameters, as well as the clinical outcomes of patients treated with drug-eluting balloon (DEB) plus bare-metal stent (BMS) versus BMS versus drug-eluting stent (DES) for ST-segment elevated acute myocardial infarction (STEMI).
BACKGROUND: Concerns remain regarding the long-term safety of DES in STEMI. DEB could provide an attractive alternative in order to achieve potentially similar effectiveness but limiting the long-term hazards related to late-acquired stent malapposition and thus stent thrombosis.
METHODS: In this randomized, international, 2-center, single-blinded, 3-arm study, STEMI patients were randomly assigned to group A: BMS; group B: DEB plus BMS; or group C: DES after successful thrombus aspiration. The primary endpoint was 6-month angiographic in-stent late-luminal loss. Secondary endpoints were in-stent binary restenosis, major adverse cardiac events (MACE: cardiac death, myocardial infarction, target vessel revascularization). In a subgroup of patients, stent (mal)apposition (by optical coherence tomography) and endothelial function (by acetylcholine infusion) was assessed.
RESULTS: Overall, 150 patients were randomized. Procedural success was achieved in 96.7%. In groups A, B, and C, respectively, late-luminal loss was 0.74 ± 0.57 mm, 0.64 ± 0.56 mm, and 0.21 ± 0.32 mm (p < 0.01); binary restenosis was 26.2%, 28.6%, and 4.7% (p = 0.01); and MACE rates were 23.5%, 20.0%, and 4.1% (p = 0.02), respectively. The median percentage [25th to 75th interquartile range] of uncovered and malapposed stent struts per lesion was 0 [0 to 0.35], 2.84 [0 to 6.63], and 5.21 [3.25 to 14.5] (p < 0.01). Significant paradoxical vasoconstriction was seen in groups B and C.
CONCLUSIONS: In STEMI patients, DEB followed by BMS implantation failed to show angiographic superiority to BMS only. Angiographic results of DES were superior to both BMS and DEB. Moreover, DEB before implantation induced more uncovered and malapposed stent struts than BMS, but less than after DES. (Drug-Eluting Balloon in Acute Myocardial Infarction [DEB-AMI]; NCT00856765).
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503057     DOI: 10.1016/j.jacc.2012.02.027

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

1.  Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial.

Authors:  Francesco Burzotta; Marta Francesca Brancati; Carlo Trani; Giancarlo Pirozzolo; Gianluigi De Maria; Antonio Maria Leone; Giampaolo Niccoli; Italo Porto; Francesco Prati; Filippo Crea
Journal:  Heart Vessels       Date:  2015-04-12       Impact factor: 2.037

Review 2.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

3.  Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group.

Authors:  Ae-Young Her; Eun-Seok Shin; Liew Houng Bang; Amin Ariff Nuruddin; Qiang Tang; I-Chang Hsieh; Jung-Cheng Hsu; Ong Tiong Kiam; ChunGuang Qiu; Jie Qian; Wan Azman Wan Ahmad; Rosli Mohd Ali
Journal:  Cardiol J       Date:  2019-09-30       Impact factor: 2.737

Review 4.  Drug-coated balloons for coronary and peripheral interventional procedures.

Authors:  Jochen Wöhrle
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

Review 5.  Drug-eluting stents versus bare-metal stents for acute coronary syndrome.

Authors:  Joshua Feinberg; Emil Eik Nielsen; Janette Greenhalgh; Juliet Hounsome; Naqash J Sethi; Sanam Safi; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2017-08-23

6.  Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy.

Authors:  Vijaya B Kolachalama; Stephen D Pacetti; Joseph W Franses; John J Stankus; Hugh Q Zhao; Tarek Shazly; Alexander Nikanorov; Lewis B Schwartz; Abraham R Tzafriri; Elazer R Edelman
Journal:  Circulation       Date:  2013-04-12       Impact factor: 29.690

Review 7.  Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group.

Authors:  Franz X Kleber; Harald Rittger; Klaus Bonaventura; Uwe Zeymer; Jochen Wöhrle; Raban Jeger; Benny Levenson; Sven Möbius-Winkler; Leonhard Bruch; Dieter Fischer; Christian Hengstenberg; Tudor Pörner; Detlef Mathey; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2013-08-28       Impact factor: 5.460

8.  Failure of drug-coated balloon angioplasty to treat bare metal in-stent restenosis accompanied by late stent thrombosis but successful treatment of binary in-stent restenosis.

Authors:  Takuya Shimizu; Jun-Ei Obata; Ken Umetani; Kiyotaka Kugiyama
Journal:  J Cardiol Cases       Date:  2019-05-16

9.  Drug-coated Balloon-only Angioplasty for Native Coronary Disease Instead of Stents.

Authors:  Upul Wickramarachchi; Simon Eccleshall
Journal:  Interv Cardiol       Date:  2016-10

Review 10.  Drug-coated balloon therapy in coronary and peripheral artery disease.

Authors:  Robert A Byrne; Michael Joner; Fernando Alfonso; Adnan Kastrati
Journal:  Nat Rev Cardiol       Date:  2013-11-05       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.